A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 2a Study With an Open-Label Extension Evaluating the Efficacy and Safety of VENT-03 in Adult Participants With Active Cutaneous Lupus Erythematosus With or Without Systemic Lupus Erythematosus

NCT07260877 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

24

Enrollment

INDUSTRY

Sponsor class

Conditions

Cutaneous Lupus Erythematosus (CLE)
Systemic Lupus Erythematosus
SLE
SLE (Systemic Lupus)
CLE

Interventions

DRUG: VENT-03
DRUG: Placebo

Sponsor

Ventus Therapeutics U.S., Inc.